Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. 

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. 

The report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase' outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 2, 1, 8 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Breast Cancer, Prostate Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Leukemias, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing and Renal Cell Carcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview 9
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 15
Products under Development by Universities/Institutes 20
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment 22
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development 28
Argos Therapeutics Inc 28
Asterias Biotherapeutics Inc 28
e-Therapeutics Plc 29
F. Hoffmann-La Roche Ltd 29
Inovio Pharmaceuticals Inc 30
Invectys SA 30
Johnson & Johnson 31
Komipharm International Co Ltd 31
Mediolanum farmaceutici SpA 32
Telocyte LLC 32
TILT Biotherapeutics Ltd 33
Ultimovacs AS 33
Vaxon Biotech 33
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles 35
AGS-499 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ASTVAC-1 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ASTVAC-2 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Dendritic Cell Therapy + TILT-234 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ETS-2300 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
GX-301 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
imetelstat sodium - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
INO-1400 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
INO-5400 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
INO-5401 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
INVAC-1 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
KML-001 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
rocapuldencel-T - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecule to Inhibit Telomerase for Lung Cancer - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
telin - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
tertomotide - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
UCPVax - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
UV-1 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Vbx-011 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Vbx-016 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Vbx-021 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Vbx-026 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vx-001 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Vx-006 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products 92
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products 95
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones 97
Featured News & Press Releases 97
Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer 97
Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress 98
Sep 12, 2017: Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress 99
Sep 11, 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma 100
Aug 21, 2017: Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress 101
Aug 14, 2017: Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2 102
Jul 31, 2017: Geron Announces Updates to Imetelstat Clinical Development 102
Jun 01, 2017: Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides 103
May 10, 2017: Argos Provides Update on its ADAPT Trial Following Meeting with FDA 104
Apr 26, 2017: Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia in 'Cancer' 105
Apr 18, 2017: Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial 106
Apr 10, 2017: Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen 107
Apr 05, 2017: Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting 109
Feb 22, 2017: Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review 109
Jan 19, 2017: Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19
Number of Products under Investigation by Universities/Institutes, H2 2017 20
Products under Investigation by Universities/Institutes, H2 2017 21
Number of Products by Stage and Mechanism of Actions, H2 2017 23
Number of Products by Stage and Route of Administration, H2 2017 25
Number of Products by Stage and Molecule Type, H2 2017 27
Pipeline by Argos Therapeutics Inc, H2 2017 28
Pipeline by Asterias Biotherapeutics Inc, H2 2017 29
Pipeline by e-Therapeutics Plc, H2 2017 29
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 29
Pipeline by Inovio Pharmaceuticals Inc, H2 2017 30
Pipeline by Invectys SA, H2 2017 31
Pipeline by Johnson & Johnson, H2 2017 31
Pipeline by Komipharm International Co Ltd, H2 2017 32
Pipeline by Mediolanum farmaceutici SpA, H2 2017 32
Pipeline by Telocyte LLC, H2 2017 32
Pipeline by TILT Biotherapeutics Ltd, H2 2017 33
Pipeline by Ultimovacs AS, H2 2017 33
Pipeline by Vaxon Biotech, H2 2017 34
Dormant Products, H2 2017 92
Dormant Products, H2 2017 (Contd..1), H2 2017 93
Dormant Products, H2 2017 (Contd..2), H2 2017 94
Discontinued Products, H2 2017 95
Discontinued Products, H2 2017 (Contd..1), H2 2017 96